It was also reported that TM acts as an opioid receptor agonist in glioma and glioblastoma cells, and inhibits cell proliferation at a range of 50–400μM without difference between glioma and glioblastoma cells by inhibiting ERK and AKT signaling pathways [41]. This evidence concerns the gene AKT1 and central nervous system cancer.